Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $338
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Madrigal Pharmaceuticals (MDGL) and raises the price target from $336 to $338.
March 08, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity maintains a Buy rating on Madrigal Pharmaceuticals and raises the price target from $336 to $338.
The increase in the price target by Canaccord Genuity reflects a positive outlook on Madrigal Pharmaceuticals, likely due to strong company fundamentals or potential market opportunities. This analyst endorsement could lead to increased investor confidence and a potential short-term uplift in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100